BEVERLY ALES: Open Payments
NPI 1174156103 · MOBILE, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,753 in 83 payments from 15 companies in 2025. Trend: 2023 $1,501 · 2024 $1,379 · 2025 $1,753
Food & beverage: $1,753
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 18 | $389 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 12 | $263 |
| Neurocrine BioSciences, Inc. | 7 | $225 |
| Vanda Pharmaceuticals Inc. | 8 | $184 |
| Lundbeck LLC | 9 | $140 |
| Boston Scientific Corporation | 4 | $103 |
| ABBVIE INC. | 6 | $98 |
| Axsome Therapeutics, Inc. | 4 | $95 |
| Corium, LLC | 7 | $94 |
| E.R. Squibb & Sons, L.L.C. | 3 | $54 |
Products named: REXULTI, CAPLYTA, INGREZZA, FANAPT, VRAYLAR, Auvelity, Azstarys, OBSIDIO.
Industry payments across AL — which companies pay providers there.
